Skip to main content

Aeglea BioTherapeutics Value Stock - Dividend - Research Selection

Aeglea BioTherapeutics

ISIN: US00773J1034, WKN: A2AG5H

Market price date: 25.09.2020
Market price: 7,06 USD




Aeglea BioTherapeutics Fundamental data and company key figures of the share

Annual reports in USD
Key figures 10-09-2020
Cash flow
Net operating cash flow -65.692.000
Capital Expenditures -1.492.000
Free cash flow -67.184.000
Balance sheet
Total Equity 60.081.000
Liabilities & Shareholders equity 83.183.000
Income statement
Net income -78.254.000
Eps (diluted) -2,450
Diluted shares outstanding 31.940.400
Net sales/revenue 100

Fundamental ratios calculated on: 25-09-2020

Ratios
Key figures 25-09-2020
Cash flow
P/C -3,28
   
P/FC -3,20
Balance sheet
ROI-94,08
ROE72,23
Income statement
P/E-2,88
Div. Yield0,00%
P/B3,58
P/S2.254.992,24


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolAGLE
Market Capitalization215.278.304,00 USD
CountryUnited States
IndicesNASDAQ Comp.
Sectors
Raw Data SourceUS GAAP in Millionen USD
Stock Split
Internethttp://www.aegleabio.com


Description of the company

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic and cancer diseases. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme which is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. Its preclinical pipeline products comprise ACN00177, a product candidate for the treatment of homocystinuria; AEB5100, a recombinant human enzyme that degrades plasma cystine and cysteine; AEB2109, an engineered human enzyme that targets the degradation of the amino acid methionine; and AEB3103, a product candidate. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, http://www.aegleabio.com